| 125.5 -2.6 (-2.03%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 154.21  |
1-year : | 160.59 |
| Resists | First : | 132.03 |
Second : | 137.5 |
| Pivot price | 130.91 |
|||
| Supports | First : | 123.19 |
Second : | 102.5 |
| MAs | MA(5) : | 128.18 |
MA(20) : | 131.15 |
| MA(100) : | 138.3  |
MA(250) : | 124.58 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 15.7 |
D(3) : | 17.6 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 156.4 | Low : | 102.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GILD ] has closed above bottom band by 3.4%. Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 129.27 - 130.05 | 130.05 - 130.63 |
| Low: | 121.39 - 122.39 | 122.39 - 123.14 |
| Close: | 124.17 - 125.67 | 125.67 - 126.78 |
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Tue, 09 Jun 2026
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Yahoo Finance
Tue, 09 Jun 2026
GILD: Strong pipeline, strategic acquisitions, and long-acting HIV therapies drive long-term growth - TradingView
Tue, 09 Jun 2026
GILD: Strong pipeline, strategic acquisitions, and disciplined growth drive long-term outlook - TradingView
Tue, 09 Jun 2026
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS - Benzinga
Mon, 08 Jun 2026
Merck (MRK) and Gilead Sciences (GILD) Achieve Key Trial Milesto - GuruFocus
Sun, 07 Jun 2026
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,240 (M) |
| Shares Float | 1,240 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 92.1 (%) |
| Shares Short | 23,140 (K) |
| Shares Short P.Month | 22,750 (K) |
| EPS | 7.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.93 |
| Profit Margin | 30.9 % |
| Operating Margin | 39.2 % |
| Return on Assets (ttm) | 13.2 % |
| Return on Equity (ttm) | 43.3 % |
| Qtrly Rev. Growth | 4.4 % |
| Gross Profit (p.s.) | 19.03 |
| Sales Per Share | 23.98 |
| EBITDA (p.s.) | 11.88 |
| Qtrly Earnings Growth | 54.7 % |
| Operating Cash Flow | 10,810 (M) |
| Levered Free Cash Flow | 7,930 (M) |
| PE Ratio | 17.07 |
| PEG Ratio | 2.1 |
| Price to Book value | 6.62 |
| Price to Sales | 5.23 |
| Price to Cash Flow | 14.39 |
| Dividend | 0.81 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|